In a dizzying reversal, Biogen announced today that it would seek approval from the U.S. Food and Drug Administration (FDA) to begin marketing its…
Longeveron’s investigational early-stage Alzheimer’s drug Lomecel-B, made from donated bone marrow, is enrolling participants for a clinical trial. Scientists have faced obstacle after obstacle…
Vaxxinity’s beta-amyloid vaccine to treat Alzheimer’s disease — UB-311 — recently received fast track designation as it finishes up Phase 2 trials. Image: Vaxxinity…
Reporter Phil Gutis reflects on the seemingly widespread disbelief that anyone diagnosed with a cognitive disease can be a productive, contributing member of society…
The Food and Drug Administration issued an update to Aduhelm’s label, now requiring a total of four MRIs during the first year of treatment…
Biogen CEO Michel Vounatsos will resign as the company begins to substantially reduce its infrastructure for producing Aduhelm. Biogen announced today that CEO Michel…
Biogen has withdrawn the application anti-amyloid Alzheimer’s drug Aduhelm from Europe’s regulatory agency. Biogen has abandoned its application for the approval of anti-amyloid Alzheimer’s…